Lower persistence of anti-nucleocapsid compared to anti-spike antibodies up to one year after SARS-CoV-2 infection
Jan Van Elslande, Matthijs Oyaert, Natalie Lorent, Yannick Vande Weygaerde, Gijs Van Pottelbergh, Lode Godderis, Marc Van Ranst, Emmanuel André, Elizaveta Padalko, Katrien Lagrou, Stien Vandendriessche, Pieter Vermeersch
Topics & Concepts
Persistence (discontinuity)AntibodySpike ProteinSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)MedicineCoronavirus disease 2019 (COVID-19)Internal medicineGastroenterologyVirologyImmunologyBiologyDiseaseInfectious disease (medical specialty)Geotechnical engineeringEngineeringSARS-CoV-2 and COVID-19 ResearchSARS-CoV-2 detection and testingCOVID-19 Clinical Research Studies